Latest from OpenAI, Anthropic, Google, Meta & more
12 stories
Tempus AI, a closely watched artificial intelligence company specializing in oncology and precision medicine, has attracted investment from Bamco Inc., one of Wall Street's most selective growth-focused asset managers, signaling deepening confidence in AI's ability to transform cancer treatment at a critical moment when the sector faces intense scrutiny over inflated valuations. The move underscores how some of the market's most discerning investors are betting that AI's real-world applications in healthcare—not just chatbots and image generators—will deliver the outsized returns that have so far eluded most AI companies beyond the mega-cap tech giants. With Tempus valued in the billions after its recent fundraising rounds, the question
7 sources
In this article, we will discuss Cathie Wood’s 2026 Portfolio: 10 Best Stocks to Buy. Ark Invest CEO Cathie Wood quickly became a Wall Street favorite back in the pandemic days with her disruptive ...
Hayden AI also claims co-founder improperly sold over $1.2M in stock.
Tempus AI Inc. on Tuesday inked a strategic collaboration agreement with Merck & Co. Inc. aimed at accelerating AI-driven precision medicine. The stock’s decline comes as broader markets experienced...
AI stocks generally rose last week as the VanEck Semiconductor ETF rose 1.8%. The sector continues to have a broad divergence as software stocks struggle in 2026 and certain segments of...